PRAME mTCR CAR T / Fred Hutchinson Cancer Center - LARVOL DELTA

Potent and Target Specific Cytotoxicity of PRAME TCR Mimic CAR T Cells in KMT2A-Rearranged AML Patient-Derived Xenograft Model (ASH 2023) - "We show potent efficacy with eradication of leukemia in PDX-bearing mice following treatment with PRAME mTCRCAR T cells resulting in prolonged survival, without hematopoietic toxicity. These results provide strong rationale for advancing this therapeutic approach to clinical development."

CAR T-Cell Therapy • Preclinical • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Melanoma • Oncology • Pediatrics • Solid Tumor • CD34 • CD8 • KMT2A • MTA2 • PRAME • PTPRC

Preclinical evaluation of targeting PRAME with TCR mimic CAR T cells in AML. (ASCO 2023) - "We demonstrate the therapeutic potential of targeting PRAME with mTCRCAR T cells in AML. We show potent efficacy with eradication of leukemia in PDX-bearing mice following treatment with PRAME mTCRCAR T cells resulting in prolonged survival. These results provide a novel approach to target PRAME with CAR T cells and provide compelling data to evaluate PRAME mTCRCAR T cells for use in clinical trials against AML."

CAR T-Cell Therapy • Preclinical • Acute Myelogenous Leukemia • Melanoma • Pediatrics • Solid Tumor • CD8 • PRAME • PTPRC

Therapeutic targeting PRAME with mTCRCAR T cells in acute myeloid leukemia. (PubMed, Blood Adv) - "Furthermore, the cytolytic activity of PRAME mTCRCAR T cells was enhanced by treating the target cells with IFN-γ, which increases PRAME antigen expression. These results demonstrate the feasibility and efficacy of targeting PRAME with novel PRAME mTCRCAR T cells."

CAR T-Cell Therapy • IO biomarker • Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Melanoma • Oncology • Solid Tumor • Testicular Cancer • HLA-A • IFNG • PRAME

Targeting PRAME with TCR-Mimic CAR T Cells in AML (ASH 2021) - "We further demonstrate that the activity of PRAME mTCR CAR T cells can be enhanced with IFN-γ treatment, providing a useful strategy to increase efficacy. Thus, the results presented provide a novel approach to target PRAME with CAR T cells and compelling data to evaluate PRAME mTCR CAR T cells in AML clinical trials."

CAR T-Cell Therapy • IO biomarker • Acute Myelogenous Leukemia • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • GLI2 • HLA-A • IFNG • IL2 • PRAME • RUNX3 • TNFA